Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.

The Progressive Supranuclear Palsy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects.

Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Progressive Supranuclear Palsy pipeline drugs market are Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, and NADPH Oxidase 4 among others. Microtubule Associated Protein Tau leads this segment of the Progressive Supranuclear Palsy pipeline drugs market.

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Targets

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by TargetsFor more Progressive Supranuclear Palsy pipeline drugs market target insights, download a free report sample

Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the Progressive Supranuclear Palsy pipeline drugs market are Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, and Major Prion Protein Inhibitor among others. Microtubule Associated Protein Tau Inhibitor leads the Progressive Supranuclear Palsy pipeline drugs market in terms of MoA.

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Mechanisms of Action

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Mechanisms of ActionFor more mechanisms of action insights into the Progressive Supranuclear Palsy pipeline drugs market, download a free report sample

Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Progressive Supranuclear Palsy pipeline drugs market are Oral, Intravenous, Subcutaneous, Intrathecal, Ophthalmic, and Topical. Oral leads the Progressive Supranuclear Palsy pipeline drugs market in terms of RoA.

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Routes of Administration

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Routes of AdministrationFor more routes of administration insights into the Progressive Supranuclear Palsy pipeline drugs market, download a free report sample

Progressive Supranuclear Palsy Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Progressive Supranuclear Palsy pipeline drugs market are Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine. Small Molecule leads the Progressive Supranuclear Palsy pipeline drugs market in terms of molecule types.

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Molecule Types

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Molecule TypesFor more molecule type insights into the Progressive Supranuclear Palsy pipeline drugs market, download a free report sample

Progressive Supranuclear Palsy Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the Progressive Supranuclear Palsy pipeline drugs market are Aprinoia Therapeutics Inc, AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Arvinas Inc, and Asahi Kasei Pharma Corp among others. Aprinoia Therapeutics Inc has the highest number of products under development.

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by Companies

Progressive Supranuclear Palsy Pipeline Drugs Market Analysis, by CompaniesTo know more about the Progressive Supranuclear Palsy pipeline drugs companies, download a free report sample

Progressive Supranuclear Palsy Pipeline Drugs Market Report Overview

Key Targets Microtubule Associated Protein Tau, Amyloid Beta A4 Protein, Protein O GlcNAcase, Alpha Synuclein, Free Radical, Major Prion Protein, and NADPH Oxidase 4 among others
Key Mechanisms of Action Microtubule Associated Protein Tau Inhibitor, Amyloid Beta A4 Protein Inhibitor, Protein O GlcNAcase Inhibitor, Alpha Synuclein Inhibitor, Free Radical Scavenger, and Major Prion Protein Inhibitor among others
Key Routes of Administration Oral, Intravenous, Subcutaneous, Intrathecal, Ophthalmic, and Topical
Key Molecule Types Small Molecule, Monoclonal Antibody, Antibody, Antisense Oligonucleotide, Gene Therapy, Gene-Modified Cell Therapy, and Subunit Vaccine
Key Companies Aprinoia Therapeutics Inc, AlzProtect SAS, New Amsterdam Sciences Inc, UCB SA, Allyx Therapeutics Inc, Alterity Therapeutics Ltd, Anhorn Medicines Co Ltd, Arvinas Inc, and Asahi Kasei Pharma Corp among others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy.
  • The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Progressive Supranuclear Palsy therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Progressive Supranuclear Palsy

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

Allyx Therapeutics Inc
Alterity Therapeutics Ltd
AlzProtect SAS
Anhorn Medicines Co Ltd
Aprinoia Therapeutics Inc
Arvinas Inc
Asahi Kasei Pharma Corp
Asceneuron SA
AZTherapies Inc
Cortice Biosciences Inc
Merck & Co Inc
NeuroTau Inc
New Amsterdam Sciences Inc
Novartis AG
Pinteon Therapeutics Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
Reata Pharmaceuticals Inc
Retrotope Inc
TauC3 Biologics Ltd
TauRx Therapeutics Ltd
Transposon Therapeutics Inc
UCB SA
Vaxxinity Inc
Verge Genomics
Voyager Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Progressive Supranuclear Palsy – Overview

Progressive Supranuclear Palsy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Progressive Supranuclear Palsy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Progressive Supranuclear Palsy – Companies Involved in Therapeutics Development

Allyx Therapeutics Inc

Alterity Therapeutics Ltd

AlzProtect SAS

Anhorn Medicines Co Ltd

Aprinoia Therapeutics Inc

Arvinas Inc

Asahi Kasei Pharma Corp

Asceneuron SA

AZTherapies Inc

Cortice Biosciences Inc

Merck & Co Inc

NeuroTau Inc

New Amsterdam Sciences Inc

Novartis AG

Pinteon Therapeutics Inc

ProMIS Neurosciences Inc

Prothena Corp Plc

Reata Pharmaceuticals Inc

Retrotope Inc

TauC3 Biologics Ltd

TauRx Therapeutics Ltd

Transposon Therapeutics Inc

UCB SA

Vaxxinity Inc

Verge Genomics

Voyager Therapeutics Inc

Progressive Supranuclear Palsy – Drug Profiles

AHT-434 – Drug Profile

Product Description

Mechanism Of Action

ALX-002 – Drug Profile

Product Description

Mechanism Of Action

Anti-tau – Drug Profile

Product Description

Mechanism Of Action

Antibodies to Inhibit Tau Protein for Progressive Supranuclear Palsy and Corticobasal Degeneration – Drug Profile

Product Description

Mechanism Of Action

APNmAb-005 – Drug Profile

Product Description

Mechanism Of Action

ASN-120290 – Drug Profile

Product Description

Mechanism Of Action

AZP-2006 – Drug Profile

Product Description

Mechanism Of Action

bepranemab – Drug Profile

Product Description

Mechanism Of Action

censavudine – Drug Profile

Product Description

Mechanism Of Action

deulinoleate ethyl – Drug Profile

Product Description

Mechanism Of Action

fasudil – Drug Profile

Product Description

Mechanism Of Action

Gene Modified Cell Therapy for Progressive Supranuclear Palsy – Drug Profile

Product Description

Mechanism Of Action

hydromethylthionine mesylate – Drug Profile

Product Description

Mechanism Of Action

MK-8719 – Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Inhibit tau Protein for Alzhiemer’s Disease and Progressive Supranuclear Palsy – Drug Profile

Product Description

Mechanism Of Action

NAS-114 – Drug Profile

Product Description

Mechanism Of Action

NAS-150 – Drug Profile

Product Description

Mechanism Of Action

NIO-752 – Drug Profile

Product Description

Mechanism Of Action

omaveloxolone – Drug Profile

Product Description

Mechanism Of Action

PNT-001 – Drug Profile

Product Description

Mechanism Of Action

PRX-005 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit Tau for Frontotemporal Lobar Dementia (FTLD), Progressive Supranuclear Palsy and Alzheimer’s Disease – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Frontotemporal Dementia, Lewy Body Dementia, Progressive Supranuclear Palsy and Schizophrenia – Drug Profile

Product Description

Mechanism Of Action

Tau – Drug Profile

Product Description

Mechanism Of Action

Tau – Drug Profile

Product Description

Mechanism Of Action

Tau Degrader – Drug Profile

Product Description

Mechanism Of Action

Tau Modulator – Drug Profile

Product Description

Mechanism Of Action

TBL-100 – Drug Profile

Product Description

Mechanism Of Action

tolfenamic acid – Drug Profile

Product Description

Mechanism Of Action

TPI-287 – Drug Profile

Product Description

Mechanism Of Action

Various Tauopathies – Drug Profile

Product Description

Mechanism Of Action

Progressive Supranuclear Palsy – Dormant Projects

Progressive Supranuclear Palsy – Discontinued Products

Progressive Supranuclear Palsy – Product Development Milestones

Featured News & Press Releases

Apr 11, 2022: APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial

Jan 20, 2022: Alzprotect completes recruitment for phase 2a clinical trial for AZP2006 in progressive supranuclear palsy (PSP)

Nov 19, 2021: Announcement of enrollment of first patient in Phase IIa clinical trial of OBP-601 (Censavudine, TPN-101) in patients with progressive supranuclear palsy (PSP)

Sep 30, 2021: Asceneuron to provide update on O-GlcNAcase Pipeline at upcoming conferences

Aug 11, 2021: Retrotope announces completion of enrollment in phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)

Jun 30, 2021: Retrotope announces initiation of phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)

May 12, 2021: Voyager Therapeutics presents new preclinical data showing reduction of pathological Tau with Vectorized Anti-Tau antibody

Feb 18, 2021: Woolsey Pharmaceuticals emerges from stealth mode to announce patients enrolled in two new CNS studies

Jan 28, 2021: Pinteon Therapeutics announces upcoming scientific presentations

Sep 14, 2020: Alzprotect forges ahead with first patients enrolled in Phase 2a study in progressive supranuclear palsy (PSP)

Apr 27, 2020: US FDA allows trial to proceed for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)

Feb 18, 2020: US FDA grants orphan drug designation for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)

Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer’s Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit

Sep 25, 2019: UCB presents UCB0107 anti-Tau immunotherapy phase I study results at World Movement Disorders Conference

Sep 18, 2019: Alzprotect gets green light from French Regulator to start phase 2a clinical trial in Progressive Supranuclear Palsy (PSP)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Progressive Supranuclear Palsy, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Progressive Supranuclear Palsy – Pipeline by Allyx Therapeutics Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Alterity Therapeutics Ltd, 2022

Progressive Supranuclear Palsy – Pipeline by AlzProtect SAS, 2022

Progressive Supranuclear Palsy – Pipeline by Anhorn Medicines Co Ltd, 2022

Progressive Supranuclear Palsy – Pipeline by Aprinoia Therapeutics Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Arvinas Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Asahi Kasei Pharma Corp, 2022

Progressive Supranuclear Palsy – Pipeline by Asceneuron SA, 2022

Progressive Supranuclear Palsy – Pipeline by AZTherapies Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Cortice Biosciences Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Merck & Co Inc, 2022

Progressive Supranuclear Palsy – Pipeline by NeuroTau Inc, 2022

Progressive Supranuclear Palsy – Pipeline by New Amsterdam Sciences Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Novartis AG, 2022

Progressive Supranuclear Palsy – Pipeline by Pinteon Therapeutics Inc, 2022

Progressive Supranuclear Palsy – Pipeline by ProMIS Neurosciences Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Prothena Corp Plc, 2022

Progressive Supranuclear Palsy – Pipeline by Reata Pharmaceuticals Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Retrotope Inc, 2022

Progressive Supranuclear Palsy – Pipeline by TauC3 Biologics Ltd, 2022

Progressive Supranuclear Palsy – Pipeline by TauRx Therapeutics Ltd, 2022

Progressive Supranuclear Palsy – Pipeline by Transposon Therapeutics Inc, 2022

Progressive Supranuclear Palsy – Pipeline by UCB SA, 2022

Progressive Supranuclear Palsy – Pipeline by Vaxxinity Inc, 2022

Progressive Supranuclear Palsy – Pipeline by Verge Genomics, 2022

Progressive Supranuclear Palsy – Pipeline by Voyager Therapeutics Inc, 2022

Progressive Supranuclear Palsy – Dormant Projects, 2022

Progressive Supranuclear Palsy – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Progressive Supranuclear Palsy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.